A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
FibroGen, Inc. (“FibroGen”) is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. We are developing FG-3246, a potential first-in-class antibody-drug conjugate (“ADC”) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (“mCRPC”) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (“PET”) biomarker and imaging agent. We anticipate initiation of a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC in mid-2025. We and our collaboration partners have developed roxadustat (爱瑞卓®, EVRENZOTM), which is currently approved in the People’s Republic of China (“China”), Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease patients on dialysis and not on dialysis.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | -118M | 30M | - | - | 235M | 176M |
| Net Income | 216M | -48M | -284M | -294M | -290M | -189M |
| EPS | $53.40 | $-12.00 | $-73.00 | $-78.50 | $-78.50 | $-52.75 |
| Free Cash Flow | -17M | -138M | -318M | -150M | -87M | 78M |
| ROIC | -90.6% | -70.1% | -76.2% | -49.3% | -29.5% | -42.3% |
| Gross Margin | - | 47.5% | - | - | 94.5% | 95.0% |
| Debt/Equity | 0.00 | -0.33 | -0.35 | -0.00 | 0.00 | 0.12 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -124M | -150M | -323M | -301M | -289M | -192M |
| Operating Margin | 0.0% | -507.8% | - | - | -122.6% | -108.8% |
| ROE | 0.0% | - | - | - | -138.7% | -44.8% |
| Shares Outstanding | 4M | 4M | 4M | 4M | 4M | 4M |
KYNTRA BIO, INC. passes 2 of 9 quality checks, indicating weak fundamentals.
KYNTRA BIO, INC. trades at 0.1x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Cheap relative to its historical range. The company's 5-year average gross margin is 79.0%. At current prices, the estimated annualized return to fair value is -6.2%.
KYNTRA BIO, INC. (KYNB) has a current P/E ratio of 0.1, compared to its historical median P/E of 15.0. The stock is currently considered Cheap based on its historical valuation range.
KYNTRA BIO, INC. (KYNB) has a 5-year average return on invested capital (ROIC) of -53.5%. This is below average and may indicate limited pricing power.
KYNTRA BIO, INC. (KYNB) has a market capitalization of $30M. It is classified as a small-cap stock.
KYNTRA BIO, INC. (KYNB) does not currently pay a regular dividend.
Based on historical P/E analysis, KYNTRA BIO, INC. (KYNB) appears cheap. The current P/E of 0.1 is 99% below its historical median of 15.0.
KYNTRA BIO, INC. (KYNB) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
KYNTRA BIO, INC. (KYNB) reported annual revenue of $30 million in its most recent fiscal year, based on SEC EDGAR filings.
KYNTRA BIO, INC. (KYNB) has a net profit margin of -160.6%. The company is currently unprofitable.
KYNTRA BIO, INC. (KYNB) generated $-138 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
KYNTRA BIO, INC. (KYNB) reported earnings per share (EPS) of $-12.00 in its most recent fiscal year.
KYNTRA BIO, INC. (KYNB) has a 5-year average gross margin of 79.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 12 years of financial data for KYNTRA BIO, INC. (KYNB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
KYNTRA BIO, INC. (KYNB) has a book value per share of $-56.90, based on its most recent annual SEC filing.
No recent press releases.